Abstract
Breast cancer (BC) is one of the commonly occurring malignancies in females worldwide. Despite significant advances in therapeutics, the mortality and morbidity of BC still lead to low survival and poor prognosis due to the drug resistance. There are certain chemotherapeutic, endocrine, and target medicines often used for BC patients, including anthracyclines, taxanes, docetaxel, cisplatin, and fluorouracil. The drug resistance mechanisms of these medicines are complicated and have not been fully elucidated. It was reported that non-coding RNAs (ncRNAs), such as micro RNAs (miRNA), long-chain non-coding RNAs (lncRNAs), and circular RNAs (circRNAs) performed key roles in regulating tumor development and mediating therapy resistance. However, the mechanism of these ncRNAs in BC chemotherapeutic, endocrine, and targeted drug resistance was different. This review aims to reveal the mechanism and potential functions of ncRNAs in BC drug resistance and to highlight the ncRNAs as a novel target for achieving improved treatment outcomes for BC patients.
Highlights
Breast cancer (BC), a complicated and heterogeneous disease which has high metastasis and recurrence rate, is a diverse hormone-dependent malignancy carcinoma and is leading in cancer mortality and morbidity globally
The results proved that miR-760 was capable of modulating the chemoresistance of BC cells through EMT
We summarized the mechanisms of non-coding RNAs (ncRNAs) in BC drug resistance, including chemotherapeutic, endocrine, and targeted drug resistance
Summary
Breast cancer (BC), a complicated and heterogeneous disease which has high metastasis and recurrence rate, is a diverse hormone-dependent malignancy carcinoma and is leading in cancer mortality and morbidity globally. More than 20 million BC patients are newly diagnosed in women worldwide [1]. Because of the heterogeneity of BC, drug resistance has become one of the major challenges. There are certain chemotherapeutic, endocrine, and targeted drugs available which have significantly improved the life quality and overall survival of patients, including anthracyclines, taxanes, cisplatin, and fluorouracil. For these therapeutic drugs, the mechanisms of drug resistance are complicated and have not been fully elucidated
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
